Fructose Intestinal Gluconeogenesis

ConditionsHealthy Participants Obese But Otherwise Healthy Participants

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age20-55

SponsorTouro University, California

About this trial

This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.

Eligibility criteria

Qualifiers

BMI 30 to 38 kg/m2 (obese group) or BMI 19 to 25 kg/m2 (lean group)

Disqualifiers

Pregnancy or lactation within the past six months;

Type 1 or 2 diabetes mellitus (including fasting glucose ≥126 mg/dL, HgbA1c ≥6.5%);

History of liver disease or AST and ALT 2x above the upper limit of normal;

Fasting triglyceride > 300 mg/dl; total cholesterol levels above the 95th percentile for age and sex;

Trial design

Treatments tested in this trial

High fructose meal
Low fructose meal
13C labeled fructose, oral
13C labeled fructose, intravenous

Treatment groups

40 Participants

are divided into 4 treatment groups

Sponsors and collaborators

Touro University, California

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Source ClinicalTrials.gov